This article is authored by Ranjit Barshikar, CEO, QbD International, CGMP Consulting, United Nations Adviser.
The US Food and Drug Administration (FDA) has issued several warning letters to pharmaceutical manufacturers in India and ...
Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...
The second indigenous CAR-T cell therapy, Qartemi, has been approved by India's drug regulator. Qartemi is a "living drug" ...
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...
Indian generic drugmaker Dr Reddy's Laboratories on Thursday said it was optimistic about the Donald Trump administration, as it believes the country would have an edge amid tensions between the ...